Skip to main content

Search

Show all results for

Home

Person

Sylvie Hauert

This person is no longer with EPFL

About
Privacy
Disclaimer

Copyright © 2025 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (4)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice

Douglas Hanahan, Mélanie Louise Tichet, Melody Swartz, Stephan Wullschleger, Gabriele Galliverti, Sylvie Hauert

Treatment of patients bearing human papillomavirus (HPV)-related cancers with synthetic long-peptide (SLP) therapeutic vaccines has shown promising results in clinical trials against premalignant lesions, whereas responses against later stage carcinomas ha ...

AMER ASSOC CANCER RESEARCH2018

Development of a nano-adjuvant cancer vaccine and its evaluation for melanoma in combination with radiotherapy

Cancer is the second leading cause of death in the world and melanoma is the deadliest type of skin cancer. Although surgery, radiotherapy and chemotherapy are still standard treatments, the discovery of the role played by the immune system in cancer has a ...

EPFL2018

Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma

Melody Swartz, Douglas Hanahan, Olivier Michielin, Krisztian Homicsko, Marcela Rincón-Restrepo, Christopher Claude Giuseppe Tremblay, Amanda Waite Lund, Laura Jeanbart, Lambert Charles François Potin, Manuel Andreas Fankhauser

In melanoma, vascular endothelial growth factor-C (VEGF-C) expression and consequent lymphangiogenesis correlate with metastasis and poor prognosis. VEGF-C also promotes tumor immunosuppression, suggesting that lymphangiogenesis inhibitors may be clinicall ...

Amer Assoc Advancement Science2017